Navigation Links
Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
Date:3/5/2013

RICHMOND, Calif., March 5, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 4:45 pm ET on Wednesday, March 13, 2013, at the Barclays Global Healthcare Conference which will be held in Miami.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2020)... ... July 22, 2020 , ... With the new school ... national attention. A new 8 page white paper, “Infectious Disease Control for Schools ... , The Germ-Fogger™ disinfecting-fogger is uniquely well suited to the requirements of disinfecting ...
(Date:7/18/2020)... , ... July 17, 2020 , ... ... COVID-19,” an extensive awareness campaign to let those who are experiencing abuse know ... seek the services they need through the Miami-Dade County’s Coordinated Victim’s Assistance Center ...
(Date:7/10/2020)... ... July 10, 2020 , ... ... company and advanced manufacturing solutions provider today announced that their CANSWAB™ nasopharyngeal swabs ... The Company has engineered a new 3D-printed swab design and has trademarked the ...
Breaking Medicine Technology:
(Date:8/7/2020)... ... 07, 2020 , ... As part of their efforts to prioritize the well-being ... Bengtson Center team decided to temporarily suspend most in-person appointments, with the exception of ... the offices now open again, the leading plastic surgeons in Michigan —Dr. Brad ...
(Date:8/5/2020)... ... 05, 2020 , ... Atlanta Magazine partnered with Castle Connolly ... “Top Doctor” survey. The mission of Castle Connolly Medical Ltd. is to help ... key medical leaders were asked to identify outstanding doctors in their respective specialties. ...
(Date:8/5/2020)... , ... August 05, 2020 , ... ... animal health industry, as president of the largest veterinarian-owned purchasing Cooperative in the ... ANIMALE in various roles where she gained extensive knowledge and experience in the ...
(Date:8/5/2020)... ... August 04, 2020 , ... Today, Power to Decide’s ... Programs (AMCHP) with the 2020 Innovation Station Best Practice Award. The One Key Question ... what circumstances to get pregnant and have a child. One Key Question is used ...
(Date:7/31/2020)... ... July 31, 2020 , ... Leaders of the Operation ... site in Savannah, GA. Visitors included Moncef Slaoui, chief advisor, and General Gustave ... announced the OWS program to accelerate the development, manufacturing, and distribution of COVID-19 ...
Breaking Medicine News(10 mins):